Indication intelligence, analysis and sector perception

Solid Biosciences (SLDB) announces acquisition of Aavanti Bio Inc (private)and concurrent $75 Million Private Placement

September 30, 2022

Solid Biosciences (SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne) and Aavanti Bio, Inc., a privately-held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, today announced that the companies have entered into a definitive merger agreement including its pipeline assets and net cash. SLDB will acquire AavantiBio, including its pipeline assets and net cash. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, led by SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne. Additional pipeline programs include AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. 

RegMed Investors’ (RMi): What’s up Applied Genetic Technologies (AGTC)?

September 28, 2022

Trying to HIDE end-of-year Annual Report (10-K) status and an S-8 registration Statement for proposed offering? Still has a “going concern” status, considered good for the time being? It means its business is facing financial distress but is still able to make payments to keep it operating at least the next 12 months. Recurring losses, accumulated deficit of $308.2 million and a fading share pricing at $0.30 with a 52-week change of -90.87% (low of $0.28 and a high of $3.295)

bluebird bio (BLUE) announced the FDA has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystro

September 21, 2022

A second approval ... Also the largest volume of three (3) session: bluebird bio (BLUE) +9.118 million shares traded (-$0.69) after Tuesday’s +21.503 million shares traded (+$0.93) after Monday’s -30.962 million share traded (-$0.41 or -6.47%) – EXPECT an offering! BLUE also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. Therapy pricing is an issue...

What's Happening Today